Related Image: Rodent fossils allows to determine climate of the Iberian Peninsula 6 million years ago |
(Date:11/6/2009)...EO, Calif., Nov. 6 ,...transfer of Qutenza(TM) E.U. Marketing Authorizati...nt progress in commercial readiness activities Ex... Director, Marketing; and Director, Commercial Ope... director and Audit Committee chairman , Up...
(Date:11/6/2009)..., Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biote...e "Company") today announced updated results from ...ients with sarcomas metastatic to the lung in a po...ssue Oncology Society Meeting held in Miami Beach,...sentation, entitled "A Phase II Study of Intraveno...
(Date:11/6/2009)... The agenda for Arrowhead’s 2010...ich is set to take place on February 22-24, 2010 i...day conference we will highlight key issues in for...share their experiences. , ...agenda for Arrowhead’s 2010 Personalized Me...
(Date:11/5/2009)...SBURG, Md., Nov. 5 GenVe...cial results for the third quarter ended September...ion ($0.04 per share) for the three months ended S...illion ($0.08 per share) in the comparable quarter...2009, GenVec,s net loss was $14.1 million ($0.15 p...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6... Biotech Ltd. (Amex:,SVA), a leading provider of v...h of Anflu(R), a seasonal influenza vaccine, for 2... Sinovac, Anflu(R) is the only split influenza,vac...vac is undertaking the,sales and marketing program...the adult dosage form of Anflu(R)., Utilizing the...
...ber 11 at 11:00 AM ET, WAYNE, Pa., Sept. 10 Enco...multinational clinical research organization,(CRO)...of the world,s,leading pharmaceutical and biotechn...nted Dr. David Ginsberg, Chief Executive Officer o...sition from Dr. Kai Lindevall, who,was named to th...
...ber of US clinics, CHICAGO, IL, Sept. 10 /PRNewsw...st commercially available bionic hand, today revea...8 National Assembly of the American,Orthotic and P...ovember 3,2008, the company,s RACE Team and Partne...rt to the growing number of prosthetics clinics th...
Other Biology Technology:Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season 2Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season 3Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors 2Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors 3Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors 4Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors 5Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors 6Touch Bionics unveils innovative partner and reimbursement programs at AOPA 2Touch Bionics unveils innovative partner and reimbursement programs at AOPA 3Rabbit Anti-D4-GDI Polyclonal Antibody, Unconjugated from Assay Designs/Stressgen Bioreagents
Rabbit Anti-MAL Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Human ADAM-12 (Meltrin alpha), amino terminal region Antibody, Unconjugated from CEDARLANE Laboratories Limited
Rabbit Anti-FLIP Polyclonal Antibody, Unconjugated from Abcam
Biology Products: